Have a personal or library account? Click to login

Quercetin, Menadione, Doxorubicin combination as a potential alternative to Doxorubicin monotherapy of acute lymphoblastic leukemia

Documenta Haematologica
Volume 34 (2015): Issue 1-2 (May 2015)
By:
Open Access
|Feb 2016

References

  1. [1] Baran I, Cell proliferation versus apoptosis. Mechanisms and particularities under genotoxic or oxidative stress conditions. “Carol Davila” University Publishing House, Bucharest, 2014
    Search in Google Scholar
  2. [2] Murakami A,Ashida H, Terao J. Multitargeted cancer prevention by quercetin. Cancer Lett 2008;269:315-2510.1016/j.canlet.2008.03.04618467024
    Search in Google Scholar
  3. [2] Baran I, Ganea C, Privitera S, Scordino A, Barresi V, Musumeci F, et. al. Detailed analysis of apoptosis and delayed luminescence of human leukemia Jurkat T cells after proton-irradiation and treatments with oxidant agents and flavonoids. Oxid Med Cell Longev. 2012;2012:498914. doi:10.1155/2012/49891410.1155/2012/498914339721022829956
    Search in Google Scholar
  4. [3] Baran I, Ionescu D, Filippi A, Mocanu M.M., Iftime A., Babes R., Tofolean I.T., Irimia R., Goicea A., Popescu V., Dimancea A., Neagu A., Ganea C., 2014. Novel insights into the antiproliferative effects and synergism of quercetin and menadione in human leukemia Jurkat T cells. Leuk Res. 2014;38(7):836-49.10.1016/j.leukres.2014.04.01024862793
    Search in Google Scholar
  5. [4] De Marchi U, Biasutto L, Garbisa S, Toninello A, Zoratti M. Quercetin can act either as an inhibitor or an inducer of the mitochondrial permeability transition pore: a demonstration of the ambivalent redox character of polyphenols. Biochim Biophys Acta. 2009;1787(12):1425-32.10.1016/j.bbabio.2009.06.00219523917
    Search in Google Scholar
  6. [5] Baran I, Ionescu D, Privitera S, Scordino A, Mocanu MM, Musumeci F, Grasso R, Gulino M, Iftime A, Tofolean IT, Garaiman A, Goicea A, Irimia R, Dimancea A, Ganea C. Mitochondrial respiratory Complex I probed by delayed luminescence spectroscopy. JBO numele complet 2013;18(12):127006.10.1117/1.JBO.18.12.12700624365956
    Search in Google Scholar
  7. [6] http://chemoth.com/types/antracyclines
    Search in Google Scholar
  8. [7]Jeong JH, An Jy, Kwon YT, Rhee JG, Lee YJ.Effects of low dose quercetin:cancer specific inhibition of cell cycle progression.J Cell Biochem 2009;106:73-8210.1002/jcb.21977273662619009557
    Search in Google Scholar
  9. [8] Yen GC, Duh PD, Tsai HL, Huang SL. Pro-oxidative properties of flavonoids in human lymphocytes.Biosci Biotechnol Biochem 2003;67:1215-2210.1271/bbb.67.121512843645
    Search in Google Scholar
  10. [9] Du G, Lin H, Wang M et al.Quercetin greatly improved therapeutic index of doxorubicin against 4T1 brest cancer by its apposite effect on HIF-1α in tumor and normal cells.Cancer Chemother Pharmacol 2010;65:277-8710.1007/s00280-009-1032-719466611
    Search in Google Scholar
  11. [10]Wang G,Zhang J, Liu L,Sharma S,Dong Q, Quercetin potentiates doxorubicin mediated antitumor effects against liver cancer through p53/Bcl-xl.PLos One 2012;7:e5176410.1371/journal.pone.0051764351988623240061
    Search in Google Scholar
  12. [11]Thorn C,Oshiro C,Altman R.B.Doxorubicin pathways:pharmacodynamics and adverse effects,Pharmacogenics and genomics
    Search in Google Scholar
  13. [12]http://elifesciences.org/content/elife/1/e00387.full.pdf
    Search in Google Scholar
  14. [13]Denard B,Lee C,Ye J 2012.Doxorubicin blocks proliferation of cancer cells through proteolytic activation of CREB3L1.eLife 1 e0009010.7554/eLife.00090352464923256041
    Search in Google Scholar
  15. [14] Baran I. et al., Cell Biochem. Biophys. 2010; 58:169-179
    Search in Google Scholar
  16. [15] Baran I. et al., Leukemia Res. 2014; 38:836-84910.1016/j.leukres.2014.04.01024862793
    Search in Google Scholar
  17. [16] Belizario JE, Alves J, Occhiucci JM, Garay-Malpartida M, Sesso A. A mechanistic view of mitochondrial death decision pores. Brazilian Journal of Medical and Biological Research. 2007;40:1011-24.10.1590/S0100-879X200600500010917665037
    Search in Google Scholar
  18. [17] Gibellini L, Pinti M, Nasi M, Montagna JP, De Biasi S, Roat E, Bertoncelli L, Cooper EL, Cossarizza A. Quercetin and cancer chemoprevention. Evid Based Complement Alternat Med. 2011;2011:591356.10.1093/ecam/neq053313671121792362
    Search in Google Scholar
  19. [18] Ferry DR,Smith A,Malkhandi J, at al. Phase 1 clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vitro tyrosine kinase inhibition.Clin Cancer Res 1996;2:659-68
    Search in Google Scholar
  20. [19] Am J Clin Nutr Oct 1, 2001, vol 74, no 4 418-42510.7861/clinmedicine.1-5-418
    Search in Google Scholar
  21. [20] Rice s.a., 2003; Loke s.a., 2008; Kanadaswami s.a., 2005
    Search in Google Scholar
DOI: https://doi.org/10.1515/dch-2015-0005 | Journal eISSN: 1582-196X
Journal RSS Feed
Language: English
Page range: 52 - 61
Published on: Feb 12, 2016
Published by: Sciendo
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year
Keywords:
doxorubicine,
quercetine,
menadione,
acute lymphoblastic leukemia,
oxidative stress
Related subjects:
Medicine,
Clinical medicine,
Internal medicine,
Haematology, oncology

© 2016 Ruxandra Irimia, Ioana Teodora Tofolean, Roxana Gabriela Sandu, Oana Elena Băran, Maria Cătălina Ceauşescu, Vlad Coşoreanu, Maria Teodora Ilie, Ramona Babeş, Constanţa Ganea, Irina Băran, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Previous articleVolume 34 (2015): Issue 1-2 (May 2015)